Cue Biopharma Stock Quote CUE - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.70

Bid

0.6803

Ask

0.77

Volume

173,530

0.70 Day's Range 0.7719

0.583 52 Week Range 3.2491

Market Cap

34.05M

Previous Close

0.7291

Open

0.72

Last Trade

496

0.7

(formt)

Last Trade Time

16:00:04

Financial Volume

$ 125,365

VWAP

0.72244

Average Volume (3m)

417,745

Shares Outstanding

48,643,316

Dividend Yield

PE Ratio

-0.67

Earnings Per Share (EPS)

-1.04

Revenue

5.49M

Net Profit

-50.73M

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant ... Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.cuebiopharma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Cue Biopharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CUE. The last closing price for Cue Biopharma was $0.73. Over the last year, Cue Biopharma shares have traded in a share price range of $ 0.583 to $ 3.2491.

Cue Biopharma currently has 48,643,316 shares outstanding. The market capitalization of Cue Biopharma is $35.47 million. Cue Biopharma has a price to earnings ratio (PE ratio) of -0.67.

Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements

Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.2	-22.2222222222	0.9	1	0.7	278655	0.8049145	CS
4	-0.05	-6.66666666667	0.75	1	0.583	274126	0.76329782	CS
12	-0.88	-55.6962025316	1.58	1.75	0.583	417745	0.93491635	CS
26	-1.63	-69.9570815451	2.33	2.358	0.583	340695	1.32825688	CS
52	-2.07	-74.7292418773	2.77	3.2491	0.583	322981	1.88370034	CS
156	-11.76	-94.3820224719	12.46	18.42	0.583	320022	4.52604426	CS
260	-6.78	-90.6417112299	7.48	35.5	0.583	305192	8.82392834	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BCDABioCardia Inc	$ 4.12 (87.27%)	1.39M
BOFBranchOut Food Inc	$ 2.05 (24.24%)	5.58M
LGHLWLion Group Holding Ltd	$ 0.0074 (19.35%)	294
AZIAutozi Internet Technology Global Ltd	3.06 (16.79%)	23.98k
NVDGraniteShares ETF Trust GraniteShares	$ 1.99 (15.03%)	21.57M
SPRCSciSparc Ltd	$ 0.33 (-22.21%)	239.75k
APLDApplied Digital Corporation	$ 3.78 (-14.29%)	241.46k
NVDUDirexion Daily NVDA Bull 2X ETF	$ 90.05 (-14.11%)	313.69k
NVDLGraniteShares ETF Trust GraniteShares	$ 55.98 (-14.09%)	9.27M
TCBPTC BioPharm Holdings PLC	$ 3.60 (-12.20%)	70.71k
NVDANVIDIA Corporation	$ 116.75 (-7.05%)	70.27M
WTOUTime Limited	$ 0.078 (-8.24%)	70.08M
NVDGraniteShares ETF Trust GraniteShares	$ 1.99 (15.03%)	21.57M
SQQQProShares UltraPro Short QQQ	$ 8.67 (2.73%)	13.08M
NVDLGraniteShares ETF Trust GraniteShares	$ 55.98 (-14.09%)	9.27M